44
Participants
Start Date
May 31, 2010
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
Placebo
A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
MEDI-570 0.03 MG
A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
MEDI-570 0.1 MG
A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
MEDI-570 0.3 MG
A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
MEDI-570 1 MG
A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
Research Site, Winston-Salem
Research Site, Columbus
Research Site, London
Research Site, Chihuahua City
Research Site, Guadalajara
Research Site, México
Research Site, Lima
Research Site, Trujillo
Research Site, Cape Town
Research Site, Johannesburg
Research Site, Long Beach
Research Site, San Leandro
Research Site, Fort Lauderdale
Research Site, Ocala
Research Site, Atlanta
Research Site, Lansing
Research Site, New York
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
MedImmune LLC
INDUSTRY